黄芪多糖联合碘-125治疗中晚期非小细胞肺癌的临床研究

目的：探讨黄芪多糖（APS）联合碘-125（I¹²⁵）治疗中晚期非小细胞肺癌（NSCLC）的临床疗效及作用机制。方法：将60例中晚期NSCLC患者随机按住院前后顺序分为观察组和对照组各30例，对照组采用I¹²⁵粒子植入方法，观察组在对照组治疗的基础上加用APS 250 mg，静脉滴注，1次/d。疗程42 d。观察治疗前患者瘤体大小，进行治疗前后KPS评分，检测治疗前后细胞免疫功能（NK，CD₃⁺，CD₄⁺，CD₈⁺）和血清癌胚抗原（CEA）和细胞角蛋白19片段（CYFRA-21-1）水平。结果：治疗后观察组和对照组总有效率分别为83.33%和73.33%，两组比较差异无显著性意义；治疗后观察组卡氏评分提高+稳定率为90.0%，优于对照组的63.3% （P<0.01）；治疗后对照组NK，CD₃⁺，CD₄⁺，CD₈⁺及CD₄⁺/CD₈⁺变化不明显，治疗后观察组NK，CD₃⁺，CD₄⁺及CD₄⁺/CD₈⁺上升并高于对照组，CD₈⁺下降并低于对照组（P<0.01）；两组血清CEA，CYFRA-21-1水平均较治疗前下降，治疗后观察组低于对照组 （P<0.01）。结论：APS联合I¹²⁵治疗中晚期NSCLC，能提高患者生活质量，提高患者免疫功能，并具有一定的抗肿瘤作用，对I¹²⁵起到增效作用，值得进一步研究。

Clinical Study of Astragal Polysaccharides Combined With Iodine-125 in Treatment of Advanced Non-small Cell Lung Cancer

Objective: To investigate the effect of Astragal Polysaccharides combined with Iodine-125(I¹²⁵)in the treatment of advanced non small cell lung cancer (NSCLC) clinical curative effect and mechanism of action. Method: A total of 60 cases of patients of advanced NSCLC were randomly by digital divided into observation group and control group with 30 cases in each group, the control group using I¹²⁵ particle implantation method, the observation group was treated with Astragal Polysaccharide (APS) 250 mg, once a day. The course of treatment was 42 days. Before treatment in patients with tumor size, KPS score before and after treatment, the cell immune function were detected before and after treatment (NK, CD₃⁺, CD₄⁺, CD₈⁺) and serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA-21-1) level. Result: after treatment, the observation group and the control group the total effective rate were 83.33% and 73.33%, no significant difference between the two groups;after treatment, the observation group KPS increase and stable rate were 90.0%, more than 63.3% of control group (P<0.01);the control group after treatment NK, CD₃⁺, CD₄⁺, CD₈⁺ and CD₄⁺/CD₈⁺ did not change significantly, after treatment were observed in group NK, CD₃⁺, CD₄⁺ and CD₄⁺/CD₈⁺ increased and higher than that of the control group, CD₈⁺ decreased and was lower than the control group(P<0.01);serum CEA, CYFRA-21-1 levels in the two groups were decreased than that before treatment, after treatment, the observation group than in the control group (P<0.01). Conclusion: APS combined with I¹²⁵ in the treatment of advanced NSCLC, can improve the quality of life of patients, improve immune function, and has certain anti tumor effect and synergistic effect on the I¹²⁵, worthy of further study.